
FDA Approves Topical JAK Inhibitor For Vitiligo
On July 19, Incyte announced that the FDA approved ruxolitinib cream 1.5% for the topical treatment of non-segmental vitiligo in adults and children over 12
On July 19, Incyte announced that the FDA approved ruxolitinib cream 1.5% for the topical treatment of non-segmental vitiligo in adults and children over 12